Atle Fund Management AB Purchases 8,299 Shares of Edwards Lifesciences Corporation $EW

Atle Fund Management AB boosted its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 14.5% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 65,659 shares of the medical research company’s stock after buying an additional 8,299 shares during the period. Edwards Lifesciences makes up approximately 2.0% of Atle Fund Management AB’s investment portfolio, making the stock its 19th largest position. Atle Fund Management AB’s holdings in Edwards Lifesciences were worth $5,106,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Econ Financial Services Corp acquired a new position in shares of Edwards Lifesciences during the second quarter worth $889,000. Fjarde AP Fonden Fourth Swedish National Pension Fund raised its position in Edwards Lifesciences by 7.0% during the 3rd quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 137,835 shares of the medical research company’s stock worth $10,719,000 after purchasing an additional 9,069 shares during the last quarter. OMERS ADMINISTRATION Corp lifted its holdings in Edwards Lifesciences by 97.3% during the 2nd quarter. OMERS ADMINISTRATION Corp now owns 44,504 shares of the medical research company’s stock worth $3,481,000 after buying an additional 21,950 shares during the period. Arkadios Wealth Advisors bought a new stake in shares of Edwards Lifesciences in the 2nd quarter valued at about $300,000. Finally, Bank of New York Mellon Corp increased its stake in shares of Edwards Lifesciences by 8.1% in the third quarter. Bank of New York Mellon Corp now owns 19,010,227 shares of the medical research company’s stock valued at $1,478,425,000 after buying an additional 1,423,365 shares during the period. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Trading Down 0.3%

NYSE:EW opened at $81.28 on Friday. Edwards Lifesciences Corporation has a 12 month low of $65.94 and a 12 month high of $87.89. The company has a current ratio of 4.00, a quick ratio of 3.29 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $47.17 billion, a price-to-earnings ratio of 35.04, a PEG ratio of 3.14 and a beta of 0.95. The firm has a fifty day simple moving average of $84.76 and a two-hundred day simple moving average of $80.99.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, October 30th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.59 by $0.08. The company had revenue of $1.55 billion for the quarter, compared to analysts’ expectations of $1.49 billion. Edwards Lifesciences had a net margin of 23.25% and a return on equity of 14.70%. The business’s revenue was up 14.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.67 EPS. Analysts expect that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CFO Scott B. Ullem sold 13,000 shares of the business’s stock in a transaction that occurred on Monday, November 10th. The stock was sold at an average price of $83.08, for a total transaction of $1,080,040.00. Following the completion of the sale, the chief financial officer owned 39,898 shares in the company, valued at $3,314,725.84. The trade was a 24.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, VP Daniel J. Lippis sold 1,020 shares of the company’s stock in a transaction that occurred on Monday, November 10th. The stock was sold at an average price of $82.55, for a total value of $84,201.00. Following the transaction, the vice president directly owned 22,002 shares in the company, valued at $1,816,265.10. The trade was a 4.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 57,824 shares of company stock valued at $4,863,323. 1.29% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several analysts recently commented on the company. Raymond James Financial upgraded Edwards Lifesciences from a “market perform” rating to an “outperform” rating and set a $96.00 target price on the stock in a report on Monday, November 3rd. Jefferies Financial Group set a $98.00 price target on shares of Edwards Lifesciences and gave the stock a “buy” rating in a research report on Wednesday, October 29th. Piper Sandler reiterated an “overweight” rating and set a $98.00 price objective (up from $95.00) on shares of Edwards Lifesciences in a research report on Tuesday, January 20th. Truist Financial set a $92.00 target price on shares of Edwards Lifesciences and gave the stock a “hold” rating in a research note on Friday, December 5th. Finally, Robert W. Baird set a $90.00 price target on shares of Edwards Lifesciences in a research report on Monday, January 12th. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $96.82.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.